LUIS ALBERTO
MENCHÉN VISO
Profesor asociado de Ciencias de la Salud
Hospital de Fuenlabrada
Fuenlabrada, EspañaHospital de Fuenlabrada-ko ikertzaileekin lankidetzan egindako argitalpenak (8)
2023
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2015
-
Incidence, management, and course of cancer in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333
2011
-
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
Gastroenterologia y Hepatologia, Vol. 34, Núm. 7, pp. 443-448
2008
-
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis
Alimentary Pharmacology and Therapeutics, Vol. 28, Núm. 5, pp. 623-628